Taysha Gene Therapies IncTSHA
Price$4.74

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $5.5M-34.2% YoYTTM through 30 Jun 2026
Net Income -$149.6MTTM through 30 Jun 2026
Free Cash Flow -$132.6MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%
Operating Margin-2,792.3%
Net Margin-2,728.0%

Returns

-38.6%ROE
-31.8%ROA

Balance Sheet Health

Debt / Equity0.23x
Current Ratio14.04x
Net Debt-$227.6Mnet cash position
Cash & Equivalents$455.4M

Quality Metrics

Altman Z-Score9.80
Piotroski F-Score3 / 9
FCF Margin-2,417.0%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'22'23'24'25
FY2025: $9.8M
Diluted EPS-$0.41TTM
'21'22'23'24'25
FY2025: $-0.34

Dividend

No dividend

Capital Allocation

Capex Intensity6.9%

Segment Performance

No segment data available.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.